Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Rakovina Therapeutics Inc. V.RKV

Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some f its products in the pipeline include kt-2000 Next Generation PARP-inhibitors, kt-3000 Dual Action DDR-inhibitors, and kt-4000 DNA...


Recent & Breaking News (TSXV:RKV)

Rakovina Therapeutics Announces Results from Annual General Meeting

GlobeNewswire June 23, 2022

Rakovina (TSXV:RKV) advancing trial programs for cancer treatment

Caroline Egan  May 27, 2022

Rakovina Therapeutics: Transform & Extend the Lives of Patients with Cancer, CEO Clip Video

Newsfile May 27, 2022

Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 26, 2022

Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas

GlobeNewswire May 11, 2022

Rakovina Therapeutics Inc. (TSXV:RKV) announces 2021 financial results and provides corporate update

Azuka Onwuka April 27, 2022

Rakovina Therapeutics Inc. Announces 2021 Financial Results and Provides Corporate Update

GlobeNewswire April 27, 2022

Rakovina Therapeutics (TSXV:RKV) presents data supporting anticancer activity for novel drug series

Caroline Egan  April 12, 2022

Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research (AACR) Annual General Meeting

GlobeNewswire April 12, 2022

Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference - Sarcomas

GlobeNewswire March 30, 2022

Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)

GlobeNewswire March 9, 2022

Rakovina Therapeutics (TSXV:RKV) president to join expert panel

Brieanna McCutcheon  January 25, 2022

Rakovina Therapeutics President to Join Expert Panel at the Fifth Annual DDR, ATR & PARP Inhibitors Summit

GlobeNewswire January 25, 2022

Rakovina Therapeutics Inc. to Present at Biotech Showcase 2022

GlobeNewswire January 6, 2022

Rakovina (TSXV:RKV) receives funding to develop anti-cancer agents

Caroline Egan  December 21, 2021

Rakovina Therapeutics Announces Non-dilutive Financial Contributions to Support Lead Optimization of Novel Anti-cancer Agents

GlobeNewswire December 21, 2021

Rakovina Therapeutics Inc. Announces Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 23, 2021

InvestmentPitch Media Video Discusses Rakovina Therapeutics' Partnership with St. Baldrick's Foundation to Research and Develop New Treatments for Childhood Bone Cancer - Video Available on Investmentpitch.com

Newsfile November 17, 2021

The Power Play by The Market Herald Releases New Interviews with Nextech AR, i-80 Gold, Kidoz Inc., Rakovina Therapeutics, Prophecy DeFi, and Saturn Oil & Gas Discussing Their Latest Press Releases

Accesswire November 16, 2021

Rakovina Therapeutics (TSXV:RKV) partners with St. Baldrick’s Foundation

Trevor Abes  November 16, 2021